BillionToOne Stock

billiontoone.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $407.89MM

BillionToOne is a molecular counter platform designed to accurately count DNA molecules to the single-count level. With a mission to detect disorders such as cystic fibrosis and sickle-cell disease, the company optimizes the signal-to-noise ratio through blood testing. The platform specializes in both prenatal and oncology divisions. BillionToOne was founded by David Tsao, Oguzhan Atay, and Sukrit Silas in 2016 and is headquartered in San Francisco, CA.

Register To Buy and Sell Shares

For more details on financing and valuation for BillionToOne, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access BillionToOne’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like BillionToOne.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

BillionToOne investors also invested in these private companies

Northwest Venture Partners
Time BioVentures
Hummingbird Ventures
U.S. Department of Health and Human Services
Civilization Ventures
NewDo Venture


Management Team

Oguzhan Atay Ph.D
David Tsao Ph.D

Frequently Asked Questions About BillionToOne’s Stock

Can you buy BillionToOne’s stock?
BillionToOne is not publicly traded on NYSE or NASDAQ in the U.S. To buy BillionToOne’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell BillionToOne’s stock?
Yes, you can sell stock of a private company like BillionToOne. Forge can help you sell your BillionToOne stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is BillionToOne’s stock price?
BillionToOne is a privately held company and therefore does not have a public stock price. However, you may access BillionToOne’s private market stock price with Forge Data.
What is BillionToOne’s stock ticker symbol?
BillionToOne does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

BillionToOne Scores $48.5 Million - Silicon Valley Daily
BillionToOne, Inc., a molecular diagnostics company, has secured an additional $48.5 million of funding from existing equity investors as well as upsized its Term Loan Facility with access to up to $35 million, with its existing lender, Bridge Bank.
Updated on: Jun 15, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.